Skip to content

Erasca

US · ERAS #2103 by market cap Listed 2021
13.61 -0.61 -4.29%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 6.00 Expensive vs history 83rd percentile
5-year average 3.68 · #407 of 514 in Biotechnology
P/E ratio -16.14 Cheap vs history 12th percentile
5-year average -6.60 · forward -22.27
P/S ratio --
5-year average 0.00

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Erasca (ERAS) 4.78B -14.03 5.21 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value20.96 Economic moatNone UncertaintyVery High

Trading 54.0% below Morningstar's fair value estimate.

Fair value

Erasca Inc earns a 4-star quantitative star rating, indicating our belief that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 25% discount to our quantitative fair value estimate of $20.96 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's liquidity bolsters our valuation estimate. Adequate liquidity allows a company to meet short-term obligations, enhancing financial stability and reducing distress risk. For example, the firm's median trading volume over the past 60 days ranks in the top 20% globally. Trading volumes are high on shares, which may indicate increased institutional interest in stock ownership. We believe this is a sign that shares could be undervalued.

Alternatively, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -2.3%, for example, lies in the bottom 30% compared with peers globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:00 · For reference only, not investment advice and not tailored to your situation.

Erasca discussion 0 comments

Add a comment